These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Canaglifozin results in cardiovascular and renal protection in patients with type 2 diabetes : from CANVAS to CREDENCE]. Scheen AJ Rev Med Liege; 2019 Oct; 74(10):508-513. PubMed ID: 31609553 [TBL] [Abstract][Full Text] [Related]
25. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. d'Emden M; Amerena J; Deed G; Pollock C; Cooper ME Diabetes Res Clin Pract; 2018 Feb; 136():23-31. PubMed ID: 29196150 [TBL] [Abstract][Full Text] [Related]
26. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Birkeland KI; Bodegard J; Norhammar A; Kuiper JG; Georgiado E; Beekman-Hendriks WL; Thuresson M; Pignot M; Herings RMC; Kooy A Diabetes Obes Metab; 2019 Apr; 21(4):968-974. PubMed ID: 30537226 [TBL] [Abstract][Full Text] [Related]
27. Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus. Hu Y Chronic Dis Transl Med; 2019 Mar; 5(1):25-36. PubMed ID: 30993261 [TBL] [Abstract][Full Text] [Related]
28. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control. Satoh H Diabetol Int; 2018 Oct; 9(4):212-214. PubMed ID: 30603370 [TBL] [Abstract][Full Text] [Related]
30. SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials. Jia X; Mehta PB; Ye Y; Alam M; Birnbaum Y; Bajaj M Curr Diab Rep; 2018 Jul; 18(9):63. PubMed ID: 29995242 [TBL] [Abstract][Full Text] [Related]
31. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914 [No Abstract] [Full Text] [Related]
32. Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. Bailey CJ; Marx N Diabetes Obes Metab; 2019 Jan; 21(1):3-14. PubMed ID: 30091169 [TBL] [Abstract][Full Text] [Related]
33. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878 [TBL] [Abstract][Full Text] [Related]
34. Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials. Mannucci E; Dicembrini I; Nreu B; Monami M Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):71-76. PubMed ID: 31757568 [TBL] [Abstract][Full Text] [Related]
35. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118 [TBL] [Abstract][Full Text] [Related]
36. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B; Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068 [TBL] [Abstract][Full Text] [Related]